(S)-1-(3-((8-(1-Ethyl-5-methyl-1H-pyrazol-4-yl)-9-methyl-9H-purin-6-yl)amino)pyrrolidin-1-yl)propan-1-one

ID: ALA4441262

Chembl Id: CHEMBL4441262

PubChem CID: 90168772

Max Phase: Preclinical

Molecular Formula: C19H26N8O

Molecular Weight: 382.47

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CCC(=O)N1CC[C@H](Nc2ncnc3c2nc(-c2cnn(CC)c2C)n3C)C1

Standard InChI:  InChI=1S/C19H26N8O/c1-5-15(28)26-8-7-13(10-26)23-17-16-19(21-11-20-17)25(4)18(24-16)14-9-22-27(6-2)12(14)3/h9,11,13H,5-8,10H2,1-4H3,(H,20,21,23)/t13-/m0/s1

Standard InChI Key:  XZTVMQMWAPLTFI-ZDUSSCGKSA-N

Alternative Forms

1. Parent:

   

   ALA4441262

   1-[(3S)-3-[[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]amino]pyrrolidin-1-yl]propan-1-one

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 382.47

Molecular Weight (Monoisotopic): 382.2230

AlogP: 1.98

#Rotatable Bonds: 5

Polar Surface Area: 93.76

Molecular Species: NEUTRAL

HBA: 8

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 3.47

CX LogP: 0.90

CX LogD: 0.90

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.73

Np Likeness Score: -1.78

References

1. Methot JL, Zhou H, Kattar SD, McGowan MA, Wilson K, Garcia Y, Deng Y, Altman M, Fradera X, Lesburg C, Fischmann T, Li C, Alves S, Shah S, Fernandez R, Goldenblatt P, Hill A, Shaffer L, Chen D, Tong V, McLeod RL, Yu H, Bass A, Kemper R, Gatto NT, LaFranco-Scheuch L, Trotter BW, Guzi T, Katz JD..  (2019)  Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability.,  62  (9): [PMID:30986068] [10.1021/acs.jmedchem.8b01818]

2. Methot JL, Zhou H, McGowan MA, Anthony NJ, Christopher M, Garcia Y, Achab A, Lipford K, Trotter BW, Altman MD, Fradera X, Lesburg CA, Li C, Alves S, Chappell CP, Jain R, Mangado R, Pinheiro E, Williams SMG, Goldenblatt P, Hill A, Shaffer L, Chen D, Tong V, McLeod RL, Lee HH, Yu H, Shah S, Katz JD..  (2021)  Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators.,  64  (8.0): [PMID:33797901] [10.1021/acs.jmedchem.1c00237]

Source

Source(1):

• Scientific Literature